Literature DB >> 18177691

Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.

Hidemichi Watari1, Yoko Ohta, Mohamed Kamel Hassan, Ying Xiong, Shinya Tanaka, Noriaki Sakuragi.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the prognostic significance of clusterin expression in invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.
METHODS: Invasive cervical cancer specimens were obtained from 52 patients who underwent radical hysterectomy and systematic lymphadenectomy at Hokkaido University Hospital from 1997 to 2004. The expression of clusterin protein was analyzed by immunohistochemical staining. Findings were evaluated in relation to several clinicopathological factors. Survival analyses were performed by the Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis.
RESULTS: Clusterin protein was present in the cytoplasm of cervical cancer cells. The expression of clusterin protein in invasive cervical cancer tissues was not related to any clinicopathologic factors analyzed. Patients with positive clusterin expression showed significantly worse prognosis than those with negative clusterin expression (p=0.017). Multivariate analysis including clusterin expression revealed that clusterin expression (p=0.006) and the number of positive node groups (p=0.002) were independent prognostic factors for survival. Survival of patients with invasive cervical cancer could be stratified into three groups by combination of clusterin expression and number of positive node groups with an estimated 5-year survival rate of 100.0% for no or one positive node group irrespective of clusterin expression (group A), 78.7% for multiple node groups with negative clusterin expression (group B), and 14.3% for multiple node groups with positive clusterin expression (group C) (p=0.03 for group A vs. group B, p=0.004 for group B vs. group C, and p<0.0001 for group A vs. group C).
CONCLUSIONS: Clusterin expression and the number of positive node groups were independent prognostic factors for invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Clusterin might be a new molecular marker to predict the survival of cervical cancer patients with multiple positive node groups.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18177691     DOI: 10.1016/j.ygyno.2007.11.026

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  Survival and prognosticators of node-positive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.

Authors:  Masayoshi Hosaka; Hidemichi Watari; Takashi Mitamura; Yousuke Konno; Tetsuji Odagiri; Tatsuya Kato; Mahito Takeda; Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2010-09-15       Impact factor: 3.402

2.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

Review 3.  Clusterin and chemoresistance.

Authors:  Julie Y Djeu; Sheng Wei
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

4.  Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer.

Authors:  David Kevans; Sheeona Gorman; Miriam Tosetto; Kieran Sheahan; Diarmuid O'Donoghue; Hugh Mulcahy; Jacintha O'Sullivan
Journal:  J Gastrointest Cancer       Date:  2012-06

Review 5.  Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes.

Authors:  Rodrigo Martins Pereira; Rania A Mekary; Kellen Cristina da Cruz Rodrigues; Chadi Pellegrini Anaruma; Eduardo Rochete Ropelle; Adelino Sanchez Ramos da Silva; Dennys Esper Cintra; José Rodrigo Pauli; Leandro Pereira de Moura
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

6.  Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy.

Authors:  Hidemichi Watari; Tatsuya Kanuma; Yoko Ohta; Mohamed Kamel Hassan; Takashi Mitamura; Masayoshi Hosaka; Takashi Minegishi; Noriaki Sakuragi
Journal:  Pathol Oncol Res       Date:  2010-01-08       Impact factor: 3.201

7.  Gelsolin and ceruloplasmin as potential predictive biomarkers for cervical cancer by 2D-DIGE proteomics analysis.

Authors:  Ilambarthi Lokamani; Mee-Lee Looi; Siti Aishah Md Ali; Ahmad Zailani Hatta Mohd Dali; Muhammad Azrif Ahmad Annuar; Rahman Jamal
Journal:  Pathol Oncol Res       Date:  2013-08-08       Impact factor: 3.201

8.  Association between clusterin polymorphisms and esophageal squamous cell carcinoma risk in Han Chinese population.

Authors:  Kun Li; Jian Wang; Zhen-Bin Ma; Guang-Hong Guo
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.

Authors:  Mohamed K Hassan; Hidemichi Watari; Yimin Han; Takashi Mitamura; Masayoshi Hosaka; Lei Wang; Shinya Tanaka; Noriaki Sakuragi
Journal:  J Exp Clin Cancer Res       Date:  2011-12-20

Review 10.  Apoptosis and molecular targeting therapy in cancer.

Authors:  Mohamed Hassan; Hidemichi Watari; Ali AbuAlmaaty; Yusuke Ohba; Noriaki Sakuragi
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.